Page last updated: 2024-09-02

senktide and sch 23390

senktide has been researched along with sch 23390 in 1 studies

Compound Research Comparison

Studies
(senktide)
Trials
(senktide)
Recent Studies (post-2010)
(senktide)
Studies
(sch 23390)
Trials
(sch 23390)
Recent Studies (post-2010) (sch 23390)
2921508030585

Protein Interaction Comparison

ProteinTaxonomysenktide (IC50)sch 23390 (IC50)
D(2) dopamine receptorHomo sapiens (human)1.0405
DRattus norvegicus (Norway rat)0.001
D(1A) dopamine receptorHomo sapiens (human)0.0461
D(1B) dopamine receptorHomo sapiens (human)0.0011
D(2) dopamine receptorRattus norvegicus (Norway rat)0.0006
Sigma non-opioid intracellular receptor 1Homo sapiens (human)0.3891

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Couture, R; De Brito Gariepy, H1

Other Studies

1 other study(ies) available for senktide and sch 23390

ArticleYear
Blockade of tachykinin NK3 receptor reverses hypertension through a dopaminergic mechanism in the ventral tegmental area of spontaneously hypertensive rats.
    British journal of pharmacology, 2010, Volume: 161, Issue:8

    Topics: Animals; Benzazepines; Blood Pressure; Dopamine; Haloperidol; Heart Rate; Hypertension; Ibotenic Acid; Indoles; Male; Oligopeptides; Peptide Fragments; Quinolines; Raclopride; Rats; Rats, Inbred SHR; Receptors, Neurokinin-3; Substance P; Ventral Tegmental Area

2010